Search results
Results from the WOW.Com Content Network
Dopamine receptors are a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS) and are implicated in many neurological processes, including motivational and incentive salience, cognition, memory, learning, and fine motor control, as well as modulation of neuroendocrine signaling.
Non-ergoline dopamine receptor agonists have higher binding affinity to dopamine D 3-receptors than dopamine D 2-receptors. This binding affinity is related to D 2 and D 3 receptor homology, the homology between them has a high degree of sequence and is closest in their transmembrane domains, were they share around 75% of the amino acid.
These agents stimulate dopamine receptors. ... Dopamine agonist; List of dopaminergic drugs; 0–9. 2-OH-NPA; ... a non-profit organization.
The mechanisms of sympathomimetic drugs can be direct-acting (direct interaction between drug and receptor), such as α-adrenergic agonists, β-adrenergic agonists, and dopaminergic agonists; or indirect-acting (interaction not between drug and receptor), such as MAOIs, COMT inhibitors, release stimulants, and reuptake inhibitors that increase the levels of endogenous catecholamines.
Modafinil is a drug that helps keep people awake and alert (wakefulness-promoting agent or "eugeroic"). [ 1 ] [ 2 ] Most of the listed modafinil analogues are drugs that specifically target dopamine reuptake (reabsorption of a neurotransmitter by a neurotransmitter transporter ) with stronger effects ( selective DRIs with improved potency ...
Esketamine (Spravato) – non-competitive NMDA receptor antagonist, other actions [13] Gepirone (Exxua) – 5-HT 1A receptor partial agonist and α 2-adrenergic receptor antagonist; Opipramol (Insidon) — σ 1 receptor agonist, other actions; Tianeptine (Stablon, Coaxil, Tianeurax) – weak and atypical μ-opioid receptor agonist, other actions
Cabergoline is a dopamine agonist. It works to reduce the amount of prolactin in the body by telling dopamine receptors to cut back, which can help to improve these symptoms.
Serotonin–dopamine releasing agents (SDRAs), for instance 5-chloro-αMT, are less common and are not selective for dopamine release, but have also been developed. [ 9 ] [ 14 ] Tryptamines like 5-chloro-αMT are the only known releaser scaffold that consistently release dopamine more potently than norepinephrine.